Company news

Cognition Therapeutics, Inc. news in 2022

Cognition Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Cognition Therapeutics Announces Participation in Sachs 6th Annual Neuroscience Forum, Biotech Showcase, and BIO Partnering @ JPM During "J.P. Morgan Week 2023"

December 20, 2022

First Participant Dosed in Europe as Cognition Therapeutics Expand Phase 2 Alzheimer's Disease Clinical Trial of Oral CT1812

December 14, 2022

Cognition Therapeutics Highlights Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy Bodies in Presentation at CTAD

November 27, 2022

Cognition Therapeutics Announces Closing of Public Offering

November 14, 2022

Cognition Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

November 13, 2022

Cognition Therapeutics Announces Pricing of Public Offering

November 9, 2022

Cognition Therapeutics is Recruiting for Lewy Body Dementia Phase 2 SHIMMER Trial in Seventeen Research Sites Across the U.S.

October 11, 2022

Cognition Therapeutics Appoints CNS Drug Development Expert to VP Clinical Development

October 10, 2022

Cognition Therapeutics Awarded $2.14 Million in Supplemental Grant Funding from NIA to Support SEQUEL Clinical Trial

September 26, 2022

Cognition Therapeutics Announces Participation in September Investment Conferences

September 5, 2022

Cognition Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

August 8, 2022

Cognition Therapeutics Doses First Patient with Dementia with Lewy Bodies in Phase 2 Clinical Study of CT1812

June 22, 2022

Cognition Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

May 10, 2022

Cognition Therapeutics to Report First Quarter 2022 Financial Results on May 11, 2022

May 3, 2022

Cognition Therapeutics Presented Preclinical Findings Showing that Sigma-2 Receptor Modulators Rescue Trafficking Deficits in Retinal Pigment Epithelial Cells in Model of Dry AMD

May 2, 2022

Cognition Therapeutics Announces Participation in B. Riley Securities 2022 Virtual Neuro & Ophthalmology Conference

April 24, 2022

Cognition Therapeutics Announces Participation in 21st Annual Needham Virtual Healthcare Conference

April 5, 2022

Cognition Therapeutics Reports Year End 2021 Financial Results and Provides Business Update

March 29, 2022

Cognition Therapeutics to Report Fourth Quarter and Full Year 2021 Results

March 21, 2022

Cognition Therapeutics Announces Participation in March Investment Conferences

March 7, 2022

Cognition Therapeutics Receives Grant from Michael J. Fox Foundation to Support Development of Sigma-2 Receptor Modulator for Parkinson’s Disease

January 3, 2022

Calls in 2022

Decks in 2022